BIG
AUPH icon

Brooklyn Investment Group’s Aurinia Pharmaceuticals AUPH Stock Holding History

Brooklyn Investment Group’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,746
Closed -$187K – 1849
2025
Q4 		$187K Buy
+11,746
New +$167K 0.01% 1389

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brooklyn Investment Group's AUPH Position: Q1 2026 in Review

Brooklyn Investment Group sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2026, closing a stake of 11,746 shares — an estimated $187K sold.

Brooklyn Investment Group first reported a position in AUPH in Q4 2025 and held it in 1 quarter. The position peaked at $187K in Q4 2025. 260 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Brooklyn Investment Group reported no remaining Aurinia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 11,746 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $187K.
  • Brooklyn Investment Group first reported a position in Aurinia Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Brooklyn Investment Group's Aurinia Pharmaceuticals position peaked at $187K in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.